Overview
This commentary, published in Journal of Patient-Reported Outcomes, explores the impact that the availability of linguistically validated COA translations can have on the ability to authentically capture the patient voice in multinational clinical trials. Gaps in translation availability can affect participant inclusion, compromise data integrity, contribute to missing endpoint data, and potentially impact regulatory acceptance of trial outcomes. The article also emphasizes the importance of early planning, stakeholder alignment, and standardized linguistic validation processes to support equitable patient participation and ensure robust, globally representative clinical trial data.
